Altavant’s lead candidate is rodatristat ethyl*, the prodrug of rodatristat, a tryptophan hydroxylase (TPH) inhibitor designed to block peripheral serotonin production. By lowering levels of serotonin in the circulation and in pulmonary tissues, rodatristat may represent a disease-modifying treatment for diseases characterized by pathological serotonin signaling. These diseases include pulmonary arterial hypertension (PAH), idiopathic pulmonary fibrosis (IPF) and sarcoidosis.
*Name applied for; application pending. For ease of reading, this website sometimes uses the name “rodatristat” to refer to the prodrug rodatristat ethyl in addition to the active moiety.